The K2/Spice Phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products

Drug Metabolism Reviews

Volumn 46, Issue 1, 2014, Pages 72-85

  Brents, Lisa K ^a   Prather, Paul L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CB2R; CP 47 497; GPCR; JWH 018; JWH 073; Substance abuse CB1R; Synthetic marijuana

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; CYCLIC AMP; DESIGNER DRUG; DRONABINOL; ENDOCANNABINOID;

ACUTE HEART INFARCTION; AGITATION; ANOREXIA; BRAIN CORTEX; BRAIN REGION; BRAIN STEM; CEREBELLUM; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COGNITIVE DEFECT; CONVULSION; CORPUS STRIATUM; DEPENDENT PERSONALITY DISORDER; DRUG DEPENDENCE; DRUG LEGISLATION; HALLUCINATION; HIPPOCAMPUS; HUMAN; HYPERTENSION; HYPOTHALAMUS; INCENSE; KIDNEY FAILURE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NAUSEA; NONHUMAN; PARANOIA; PSYCHOSIS; PULSE RATE; REVIEW; SIGNAL TRANSDUCTION; SOLID PHASE EXTRACTION; SUBSTANCE ABUSE; SUICIDE; TACHYCARDIA; UNITED STATES; UPREGULATION; VOMITING; XEROSTOMIA;

ANIMALS; CANNABINOIDS; CYCLOHEXANOLS; HUMANS; INDOLES; NAPHTHALENES; PLANT EXTRACTS; STREET DRUGS;

EID: 84893220502     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2013.839700     Document Type: Review

References (158)

1. AAPCC (2011). Synthetic marijuana data. [Online] Available from: http://www.aapcc.org/dnn/Portals/0/ Synthetic%20Marijuana%20Data%20for%20Website%2012.12.2011.- pdf [last accessed 17 Dec 2011].
2. AAPCC (2013). Synthetic marijuana data [Online]. Available from: https://aapcc.s3.amazonaws.com/files/library/Synthetic-Marijuana-Data-for- Website-5.31.2013.pdf [last accessed 6 Jun 2013].
3. Allsop DJ, Copeland J, Norberg MM, et al. (2012). Quantifying the clinical significance of cannabis withdrawal. PLoS One 7:e44864.
4. Ashton JC, Rahman RM, Nair SM, et al. (2007). Cerebral hypoxiaischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412: 114-117.
5. Atwood BK, Huffman J, Straiker A, Mackie, K. (2010). JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160: 585-593.
6. Atwood BK, Lee D, Straiker A, et al. (2011). CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139-145.
7. Auwarter V, Dresen S, Weinmann W, et al. (2009). 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832-837.
8. Basu S, Dittel, BN. (2011). Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51:26-38.
9. Bhanushali GK, Jain G, Fatima H, et al. (2013). AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol 8: 523-526.
10. Boone, C. (2012). Teen's death officically linked to synthetic pot. The Atlanta Journal-Constitution [Online]. Available from: http://www.ajc.com/news/ news/local/teens-death-officially-linked-to-syntheticpot/nQWKk/[last accessed 25 Sep 2012].
11. Bosier B, Hermans E, Lambert, D. (2008). Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br J Pharmacol 155: 24-33.
12. Bosier B, Muccioli GG, Hermans E, Lambert, DM. (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80:1-12.
13. Bouaboula M, Poinot-Chazel C, Bourrie B, et al. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641.
14. Brents LK, Gallus-Zawada A, Radominska-Pandya A, et al. (2012). Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH- 073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol 83:952-961.
15. Brents LK, Reichard EE, Zimmerman SM, et al. (2011). Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917.
16. Brents LK, Zimmerman SM, Saffell AR, et al. (2013). Differential drug- drug interactions of the synthetic cannabinoids JWH-018 and JWH- 073: implications for drug abuse and pain therapy. J Pharmacol Exp Therapeutics 346:350-361.
17. Brighton PJ, Marczylo TH, Rana S, et al. (2011). Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium. Br J Pharmacol 164:1479-1494.
18. Bronstein AC, Spyker DA, Cantilena LR, et al. (2011). 2010 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 49:910-941.
19. CBP.GOV (2009). Lab results confirm CBP in Ohio Discover Synthetic Narcotics in Incense Packets. U.S. Customs and Border Protection News Release [Online]. Available from: http://www.cbp.gov/archived/xp/cgov/newsroom/news- releases/archives/2009-news-releases/january- 2009/01142009-3.xml.html [last accessed 7 Jul 2013].
20. Chimalakonda KC, Bratton SM, Le VH, et al. (2011). Conjugation of Synthetic Cannabinoids, JWH-018 [Naphthalen-1-yl-(1-pentylindol- 3-yl)methanone] and JWH-073 [naphthalen-1-yl-(1-butylindol-3- yl)methanone], Metabolites by Human UDP-glucuronosyltransferases. Drug Metab Dispos 39:1967-1976.
21. Chimalakonda KC, Seely KA, Bratton SM, et al. (2012). Cytochrome p450-mediated oxidative metabolism of abused synthetic cannabinoids found in k2/spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174-2184.
22. Cohen J, Morrison S, Greenberg J, Saidinejad M. (2012). Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 129:e1064-e1067.
23. Condie R, Herring A, Koh WS, et al. (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL- 2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271: 13175-13183.
24. Couch RA, Madhavaram H. (2012). Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. Drug Test Anal 4:409-414.
25. Crippa JA, Hallak JE, Machado-de-Sousa JP, et al. (2012). Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. J Clin Pharm Ther 38:162-164.
26. Department of Justice (2011). Schedules of controlled substances: temporary placement of five synthetic cannabinoids into schedule I. [Online] Available from: http://www.gpo.gov:80/fdsys/pkg/FR-2011- 03-01/pdf/2011-4428.pdf [last accessed 07 Dec 2012].
27. Dresen S, Ferreiros N, Putz M, et al. (2010). Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 45:1186-1194.
28. Drugs-Forum. (2009). Snorting JWH-018. Substance information network (S.I.N.) foundation. [Online] Available from: http://www.drugsforum. com/forum/showthread.php?t=101492 [last accessed 26 Sep 2012].
29. Drugs-Forum. (2010a). JWH-018 for a non-smoker and a person with new home/insufflation. Substance Information Network (S.I.N.) Foundation. [Online] Available from: http://www.drugs-forum.com/forum/showthread.php?t=127290 [last accessed 26 Sep 2012].
30. Drugs-Forum. (2010b). Experiencing the addictive properties of synthetic cannabinoids. Substance Information Network (S.I.N.) Foundation. [Online] Available from: http://www.drugs-forum.com/forum/showthread.php?t124787 [last accessed 26 Sep 2012].
31. Drugs-Forum. (2011). Am-2201 addiction⋯Seeking advice. Substance Information Network (S.I.N.) Foundation. [Online] Available from: http://www.drugs-forum.com/forum/showthread.php?t168986 [last accessed 26 Sep 2012].
32. Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D. (2013). Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses. DOI 10.3371/CSRP.DUDE.031513.
33. ElSohly MA, GulW, ElSohly KM, et al. (2011). Liquid chromatographytandem mass spectrometry analysis of urine specimens for K2 (JWH- 018) metabolites. J Anal Toxicol 35:487-495.
34. EMCDDA (2009). EMCDDA-Europol 2008 Annual Report on the implementation of Council Decision 2005/387/JHA. Lisbon. [Online] Available from: http://www.emcdda.europa.eu/attachements.cfm/att-132902-EN-2008- Implementation%20report.pdf [last accessed 7 Dec 2012].
35. Englund A, Morrison PD, Nottage J, et al. (2012). Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19-27.
36. Ernst L, Kruger K, Lindigkeit R, et al. (2012). Synthetic cannabinoids in "spice-like" herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market. Forensic Sci Int 222:216-222.
37. Ernst L, Schiebel HM, Theuring C, et al. (2011). Identification and characterization of JWH-122 used as new ingredient in "Spice-like" herbal incenses. Forensic Sci Int 208:e31-e35.
38. Every-Palmer, S. (2011). Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug Alcohol Depend 117: 152-157.
39. Fadda P, Scherma M, Spano MS, et al. (2006). Cannabinoid selfadministration increases dopamine release in the nucleus accumbens. Neuroreport 17:1629-1632.
40. Farkas I, Kallo I, Deli L, et al. (2010). Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. Endocrinology 151: 5818-5829.
41. Felder CC, Joyce KE, Briley EM, et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
42. Franklin JM, Carrasco GA. (2013). Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse 67:145-159.
43. Franklin JM, Mathew M, Carrasco GA. (2013). Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett 548:165-169.
44. Fulp A, Bortoff K, Zhang Y, et al. (2012). Diphenyl purine derivatives as peripherally selective cannabinoid receptor 1 antagonists. J Med Chem 55:10022-10032.
45. Galiegue S, Mary S, Marchand J, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
46. Ginsburg BC, Mcmahon LR, Sanchez JJ, Javors MA. (2012). Purity of synthetic cannabinoids sold online for recreational use. J Anal Toxicol 36:66-68.
47. Glass M, Felder CC. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
48. Glass M, Northup JK. (1999). Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56: 1362-1369.
49. Goldschmidt L, Richardson GA, Willford JA, et al. (2012). School achievement in 14-year-old youths prenatally exposed to marijuana. Neurotoxicol Teratol 34:161-167.
50. Gonzalez R, Schuster RM, Mermelstein RJ, et al. (2012). Performance of young adult cannabis users on neurocognitive measures of impulsive behavior and their relationship to symptoms of cannabis use disorders. J Clin Exp Neuropsychol 34:962-976.
51. Gottardo R, Chiarini A, Dal Pra I, et al. (2012). Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J Mass Spectrom 47:141-146.
52. Goupil E, Laporte SA, Hebert TE. (2012). Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations. Mini Rev Med Chem 12:817-830.
53. Grabenauer M, Krol WL, Wiley JL, Thomas BF. (2012). Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. Anal Chem 84:5574-5581.
54. Grant JE, Chamberlain SR, Schreiber L, Odlaug BL. (2012). Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend 121:159-162.
55. Griffiths P, Sedefov R, Gallegos A, Lopez D. (2010). How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study. Addiction 105:951-953.
56. Grotenhermen F, Muller-Vahl K. (2012). The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 109:495-501.
57. GW Pharmaceuticals (2012a). Third phase III Sativex cancer pain trial commences [Online]. Available from: http://www.gwpharm.com/ Third%20phase%20III%20Sativex%20cancer%20pain%20trial%20 commences.aspx [last accessed 06 Dec 2012].
58. GW Pharmaceuticals (2012b). Package leaflet: Information for the patient, Sativex Oromucosal Spray [Online] Available from: www.medicines.org.uk/EMC/ pdfviewer.aspx?isAttachmenttrueand documentid23228 [last accessed 06 Dec 2012].
59. Habayeb OM, Taylor AH, Bell SC, et al. (2008). Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology 149:5052-5060.
60. Harris CR, Brown, A. (2012). Synthetic cannabinoid intoxication: a case series and review. J Emerg Med 44:360-366.
61. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. (2012). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction 108:534-544.
62. Hill AJ, Weston SE, Jones NA, et al. (2010). Delta- Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia 51:1522-1532.
63. Horne AW, Phillips 3rd JA, Kane N, et al. (2008). CB1 expression is attenuated in Fallopian tube and decidua of women with ectopic pregnancy. PLoS One 3:e3969.
64. Hu X, Primack BA, Barnett TE, Cook RL. (2011). College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy 6:16-20.
65. Huang CC, Lo SW, Hsu KS. (2001). Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748.
66. Hudson S, Ramsey J, King L, et al. (2010). Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products. J Anal Toxicol 34:252-260.
67. Jin MJ, Lee J, In MK, Yoo HH. (2012). Characterization of in vitro metabolites of cp 47,497, a synthetic cannabinoid, in human liver microsomes by LC-MS/MS. J Forensic Sci 58:195-199.
68. Jinwala FN, Gupta M. (2012). Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol 22:459-462.
69. Johnston LD, Malley PM, Bachman JG, Schulenberg JE. (2011). Marijuana use continues to rise among U.S. teens, while alcohol use hits historic lows. [Online] Available from: http://www.monitoringthefuture. org [last accessed 16 Dec 2011].
70. Kneisel S, Westphal F, Bisel P, et al. (2012). Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1- pentylindole as an additive in 'herbal incense'. J Mass Spectrom 47: 195-200.
71. Kovacs FE, Knop T, Urbanski MJ, et al. (2012). Exogenous and endogenous cannabinoids suppress inhibitory neurotransmission in the human neocortex. Neuropsychopharmacology 37:1104-1114.
72. Kunos G, Tam, J. (2011). The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163:1423-1431.
73. Lauckner JE, Hille B, Mackie, K. (2005). The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 102: 19144-19149.
74. Leweke FM, Piomelli D, Pahlisch F, et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94.
75. Lewis SE, Paro R, Borriello L, et al. (2012). Long-term use of HU210 adversely affects spermatogenesis in rats by modulating the endocannabinoid system. Int J Androl 35:731-740.
76. Ligresti A, Moriello AS, Starowicz K, et al. (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375-1387.
77. Lindigkeit R, Boehme A, Eiserloh I, et al. (2009). Spice: a never ending story? Forensic Sci Int 191:58-63.
78. Liu X, Jutooru I, Lei P, et al. (2012). Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 11: 1421-1431.
79. Lodish H, Berk A, Kaiser CA, et al. (2012). Molecular cell biology, 7th ed. New York: W.H. Freeman.
80. Lombard C, Nagarkatti M, Nagarkatti, P. (2007). CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 122:259-270.
81. Lou ZY, Chen C, He Q, et al. (2011). Targeting CB(2) receptor as a neuroinflammatory modulator in experimental autoimmune encephalomyelitis. Mol Immunol 49:453-461.
82. Mackie K. (2005). Cannabinoid receptor homo- and heterodimerization. Life Sci 77:1667-1673.
83. Mackie K, Lai Y, Westenbroek R, Mitchell R. (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15:6552-6561.
84. Maneuf YP, Brotchie JM. (1997). Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398.
85. Martin-Moreno AM, Brera B, Spuch C, et al. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers betaamyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9:8.
86. Maurer HH, Sauer C, Theobald DS. (2006). Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 28:447-453.
87. Mayo N. (2011). Coroner: Lamar Jack ingested chemical found in fake marijuana before he died. Anderson Independent Mail [Online]. Available from: http://www.independentmail.com/news/2011/oct/15/coroner-lamar-jack-ingested- chemical-found-fake-ma/[last accessed 6 Dec 2012].
88. Mcallister SD, Griffin G, Satin LS, Abood ME. (1999). Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291:618-626.
89. Mcintosh BT, Hudson B, Yegorova S, et al. (2007). Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152:1111-1120.
90. Mcquade D, Hudson S, Dargan PI, Wood DM. (2012). First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 69:373-376.
91. Mechoulam R, Parker LA. (2012). The endocannabinoid system and the brain. Annu Rev Psychol 64:21-47.
92. Meier MH, Caspi A, Ambler A, et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109:E2657-E2664.
93. Merola G, Aturki Z, D'orazio G, et al. (2012). Analysis of synthetic cannabinoids in herbal blends by means of nano-liquid chromatography. J Pharm Biomed Anal 71:45-53.
94. Mir A, Obafemi A, Young A, Kane, C. (2011). Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128: e1622-e1627.
95. Moller I, Wintermeyer A, Bender K, et al. (2011). Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal 3:609-620.
96. Montgomery C, Seddon AL, Fisk JE, et al. (2012). Cannabis-related deficits in real-world memory. Hum Psychopharmacol 27:217-225.
97. Moran CL, Le VH, Chimalakonda KC, et al. (2011). Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 83:4228-4236.
98. Morrison PD, Zois V, McKeown DA, et al. (2009). The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 39:1607-1616.
99. Musah RA, Domin MA, Cody RB, et al. (2012). Direct analysis in real time mass spectrometry with collision-induced dissociation for structural analysis of synthetic cannabinoids. Rapid Commun Mass Spectrom 26:2335-2342.
100. Musshoff F, Madea B, Kernbach-Wighton G, et al. (2013). Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med DOI 10.1007/s00414-013-0864-1.
101. National Conference of State Legislatures (2012). Synthetic CAnnabinoids (a.k.a. "K2/"Spice) enactments [Online]. Available from: http://www.ncsl.org/issues-research/justice/synthetic-cannabinoids- enactments.aspx [last accessed 11 Oct 2012].
102. Office of Diversion Control (2009). National Forensic Laboratory Information System: Year 2008 annual report. Washington, DC: U.S. Drug Enforcement Administration. [Online] Available from: www.deadiversion.usdoj.gov/ nflis/2008annual-rpt.pdf [last accessed 7 Dec 2012].
103. Office of Diversion Control (2011). Special report: synthetic cannabinoids and synthetic cathinones reported in National Forensic Laboratory Information System, 2009-2010. Springfield (VA): U.S. Drug Enforcement Administration. [Online] Available from: www.deadiversion. usdoj.gov/nflis/ 2010rx-synth.pdf [last accessed 7 Dec 2012].
104. Office of Diversion Control (2012). National Forensic Laboratory Information System: Midyear report 2011. Springfield (VA): U.S. Drug Enforcement Administration. [Online] Available from: http://www.deadiversion.usdoj.gov/ nflis/2011midyear.pdf [last accessed 7 Dec 2012].
105. Patton AC, Moran C, McCain K, et al. (2013). K2 toxicity: Fatal case of psychiatric complications following AM2201 exposure. J Forensic Sci DOI 10.1111/1556-4029.12216.
106. Pertwee RG. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199-215.
107. Pertwee RG, Howlett AC, Abood ME, et al. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB and CB. Pharmacol Rev 62:588-631.
108. Price DA, Martinez AA, Seillier A, et al. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29:2177-2186.
109. Psychoyos D, Vinod KY, Cao J, et al. (2012). Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res B Dev Reprod Toxicol 95:137-150.
110. Psychonaut Web Mapping Research Group (2009). Spice report. [Online] Available from: http://www.psychonautproject.eu/documents/reports/Spice.pdf [last accessed 07 Dec 2012].
111. Psychoyos D, Vinod KY. (2012). Marijuana, spice 'herbal high', and early neural development: implications for rescheduling and legalization. Drug Test Anal 5:27-45.
112. Rajasekaran M, Brents LK, Franks LN, et al. (2013). Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors. Toxicol Appl Pharmacol 269:100-108.
113. Regard JBS, Coughlin SR. (2008a) Anatomical profiling of CB1R expression [Online]. Available from: http://pdsp.med.unc.edu/ShaunCell/webfiles/ Cnr1%20graph%201.jpg.800.jpg [last accessed 18 Jul 2013].
114. Regard JBS, Coughlin, S.R. (2008b) Antomical profiling of CB2R expression [Online]. Available from: http://pdsp.med.unc.edu/ShaunCell/webfiles/ Cnr2%20graph%201.jpg.800.jpg [last accessed 18 Jul 2013].
115. Riedel G, Fadda P, McKillop-Smith S, et al. (2009). Synthetic and plantderived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156:1154-1166.
116. Rivera P, Luque-Rojas MJ, Pastor A, et al. (2012). Diet-dependent modulation of hippocampal expression of endocannabinoid signalingrelated proteins in cannabinoid antagonist-treated obese rats. Eur J Neurosci 37:105-117.
117. Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
118. Sanchez Robles EM, Bagues Arias A, Martin Fontelles MI. (2012). Cannabinoids and muscular pain: Effectiveness of the local administration in rat. Eur J Pain 16:1116-1127.
119. Savini D. (2011). 2 Investigators: Synthetic marijuana product blamed in teen's deadly crash. CBS Chicago [Online]. Available from: http://chicago. cbslocal.com/2011/07/07/2-investigators-synthetic-marijuana- product-blamed-in-teens-deadly-crash/[last accessed 06 Dec 2012].
120. Schecter A, Brian R. (2011). Retailers selling legal high "Time Bombs" to kids, doctor says. ABC News [Online]. Available from: http://abcnews.go.com/Blotter/retailers-selling-legal-high-time-bombs- kidsdoctor/story?id=13753898 [last accessed 25 Sep 2012].
121. Schubart CD, Sommer IE, van Gastel WA, et al. (2011). Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res 130:216-221.
122. Seely KA, Lapoint J, Moran JH, Fattore L. (2012). Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234-243.
123. Sekula K, Zuba D, Stanaszek, R. (2012). Identification of naphthoylindoles acting on cannabinoid receptors based on their fragmentation patterns under ESI-QTOFMS. J Mass Spectrom 47:632-643.
124. Shim JY, Bertalovitz AC, Kendall, D. A. (2012). Probing the Interaction of SR141716A with the CB1 Receptor. J Biol Chem 287: 38741-38754.
125. Shoemaker JL, Ruckle MB, Mayeux PR, Prather, P. L. (2005). Agonistdirected trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 315:828-838.
126. Shoemaker JL, Seely KA, Reed RL, et al. (2007). The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 101:87-98.
127. Singh UP, Singh NP, Singh B, et al. (2012). Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. Toxicol Appl Pharmacol 258:256-267.
128. Sobolevsky T, Prasolov I, Rodchenkov G. (2010). Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 200:141-147.
129. Sobolevsky T, Prasolov I, Rodchenkov G. (2012). Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal DOI 10.1002/dta.1418.
130. Steup C. (2008). Untersuchung des handelsproduktes "Spice" (Investigation of the commercial product "Spice"). Frankfurt, Germany: THC Pharm GmbH [Online] Available from: http://usualredant.de/downloads/ analyse-thc-pharm-spice-jwh-018.pdf [last accessed 07 Dec 2012].
131. Straiker A, Mackie K. (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501-517.
132. Sun X, Dey SK. (2012). Endocannabinoid signaling in female reproduction. ACS Chem Neurosci 3:349-355.
133. Surugiu ME, Minca DG. (2012). European dimension of cannabinoidlike products use. J Med Life 5:79-81.
134. Szabo B, Siemes S, Wallmichrath I. (2002). Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 15:2057-2061.
135. Taffe MA. (2012). Delta(9) tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. J Psychopharmacol 26:1299-1306.
136. Thalji J. (2012). Use of synthetic marijuana linked to drowning death of Clearwater teen. Tampa Bay Times [Online]. Available from: http://www.tampabay. com/news/publicsafety/use-of-synthetic-marijuanalinked- to-drowning-death-of- clearwater-teen/1223770 [last accessed 25 Sep 2012].
137. Tofighi B, Lee JD. (2012). Internet highs - Seizures after consumption of synthetic cannabinoids purchased online. J Addict Med 6: 240-241.
138. Tung CK, Chiang TP, Lam M. (2012). Acute mental disturbance caused by synthetic cannabinoid: a potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry 22:31-33.
139. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. (2010). Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int 198:31-38.
140. Unimed Pharmaceuticals (2004). Marinol (Dronabinol) new drug application. FDA [Online] Available from: http://www.fda.gov/ohrms/dockets/dockets/05n0479/ 05N-0479-emc0004-04.pdf [last accessed 02 Jan 2013].
141. United States 21 U.S.C. x 813 (1986) Treatment of controlled substance analogues. U.S. Government Printing Office. pp. 452 [Online]. Available from: http://www.gpo.gov:80/fdsys/pkg/USCODE-2008- title21/pdf/USCODE-2008-title21- chap13-subchapI-partB-sec813.pdf [last accessed 01 Jan 2013].
142. United States (2012). Synthetic drug abuse prevention act of 2012. U.S. Government Printing Office. pp. 138-140. [Online] Available from: http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr/pdf/BILLS- 112s3187enr.pdf [last accessed 7 Dec 2013].
143. Valdeolivas S, Satta V, Pertwee RG, et al. (2012). Sativex-like combination of phytocannabinoids is neuroprotective in malonatelesioned rats, an inflammatory model of Huntington's disease: Role of CB(1) and CB(2) receptors. ACS Chem Neurosci 3:400-406.
144. Valoti E, Casagni E, Dell'Acqua L, et al. (2012). Identification of 1- butyl-3-(1-(4-methyl)naphtoyl)indole detected for the first time in "herbal high" products on the Italian market. Forensic Sci Int 223: e42-e46.
145. Vandrey R, Dunn KE, Fry JA, Girling ER. (2011). A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 120:238-241.
146. Vardakou I, Pistos C, Spiliopoulou, C. (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197: 157-162.
147. Vidinsky B, Gal P, Pilatova M, Vidova Z, et al. (2012). Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. Folia Biol (Praha) 58:75-80.
148. Walter L, Franklin A, Witting A, et al. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405.
149. Westphal F, Sonnichsen FD, Thiemt, S. (2012). Identification of 1-butyl- 3-(1-(4-methyl)naphthoyl)indole in a herbal mixture. Forensic Sci Int 215:8-13.
150. Wintermeyer A, Moller I, Thevis M, et al. (2010). In vitro phase I metabolism of the synthetic cannabimimetic JWH-018.
151. Anal Bioanal Chem 398:2141-2153.
152. World Health Organization (2012). Management of substance abuse [Online]. Available: http://www.who.int/substance-abuse/facts/cannabis/en/[last accessed 02 Jan 2013].
153. Zarruk JG, Fernandez-Lopez D, Garcia-Yebenes I, et al. (2012). Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 43:211-219.
154. Zhang Q, Ma P, Cole RB, Wang G. (2006). Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal Bioanal Chem 386:1345-1355.
155. Zhang Q, Ma P, Iszard M, et al. (2002). In vitro metabolism of R(+)- [2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4- benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos 30:1077-1086.
156. Zimmermann US, Winkelmann PR, Pilhatsch M, et al. (2009). Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 106:464-467.
157. Zuardi AW. (2006). History of cannabis as a medicine: a review. Rev Bras Psiquiatr 28:153-157.
158. Zuba D, Byrska B, Maciow M. (2011). Comparison of "herbal highs" composition. Anal Bioanal Chem 400:119-126.